Advertisement

Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer

      Abstract

      Introduction

      The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non–muscle-invasive bladder cancer (NMIBC).

      Patients and Methods

      The study period was from January 2002 through December 2012. A total of 1046 patients with primary T1 HG/G3 who had NMIBC on re-transurethral bladder resection (TURB) who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance from 13 academic institutions were included. Endpoints were time to disease, and recurrence-free (RFS), progression-free (PFS), overall (OS), and cancer-specific survival (CSS).

      Results

      A total of 512 (48.9%) of patients had NLR ≥ 3 prior to TURB. High pretreatment NLR was associated with female gender and residual T1HG/G3 on re-TURB. The 5-year RFS estimates were 9.4% (95% confidence interval [CI], 6.8%-12.4%) in patients with NLR ≥ 3 compared with 58.8% (95% CI, 54%-63.2%) in patients with NLR < 3; the 5-year PFS estimates were 57.1% (95% CI, 51.5%-62.2%) versus 79.2% (95% CI, 74.7%-83%; P < .0001); the 10-year OS estimates were 63.6% (95% CI, 55%-71%) versus 66.5% (95% CI, 56.8%-74.5%; P = .03); the 10-year CSS estimates were 77.4% (95% CI, 68.4%-84.2%) versus 84.3% (95% CI, 76.6%-89.7%; P = .004). NLR was independently associated with disease recurrence (hazard ratio [HR], 3.34; 95% CI, 2.82-3.95; P < .001), progression (HR, 2.18; 95% CI, 1.71-2.78; P < .001) and CSS (HR, 1.65; 95% CI, 1.02-2.66; P = .03). The addition of NLR to a multivariable model that included established features increased its discrimination for predicting of RFS (+6.9%), PFS (+1.8%), and CSS (+1.7%).

      Conclusions

      Pretreatment NLR ≥ 3 was a strong predictor for RFS, PFS, and CSS in patients with primary T1 HG/G3 NMIBC. It could help in the decision-making regarding intensity of therapy and follow-up.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Burger M.
        • Catto J.W.F.
        • Dalbagni G.
        • et al.
        Epidemiology and risk factors of urothelial bladder cancer.
        Eur Urol. 2013; 63: 234-241
        • Kamat A.M.
        • Hegarty P.K.
        • Gee J.R.
        • et al.
        ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers.
        Eur Urol. 2013; 63: 4-15
        • Babjuk M.
        • Böhle A.
        • Burger M.
        • et al.
        EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.
        Eur Urol. 2017; 71: 447-461
        • Fajkovic H.
        • Halpern J.A.
        • Cha E.K.
        • et al.
        Impact of gender on bladder cancer incidence, staging, and prognosis.
        World J Urol. 2011; 29: 457-463
        • Sylvester R.J.
        • van der Meijden A.P.M.
        • Oosterlinck W.
        • et al.
        Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
        Eur Urol. 2006; 49 ([discussion: 475-477]): 466-475
        • Xylinas E.
        • Kent M.
        • Kluth L.
        • et al.
        Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
        Br J Cancer. 2013; 109: 1460-1466
        • Gupta A.
        • Lotan Y.
        • Bastian P.J.
        • et al.
        Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
        Urology. 2008; 71: 302-307
        • Kluth L.A.
        • Black P.C.
        • Bochner B.H.
        • et al.
        Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature.
        Eur Urol. 2015; 68: 238-253
        • Fritsche H.-M.
        • Burger M.
        • Svatek R.S.
        • et al.
        Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
        Eur Urol. 2010; 57: 300-309
        • Mukherjee N.
        • Cardenas E.
        • Bedolla R.
        • Ghosh R.
        SETD6 regulates NF-κB signaling in urothelial cell survival: implications for bladder cancer.
        Oncotarget. 2017; 8: 15114-15125
        • Li X.
        • Ma X.
        • Tang L.
        • et al.
        Prognostic value of neutrophil-to-lymphocyte ratio in urothelial carcinoma of the upper urinary tract and bladder: a systematic review and meta-analysis.
        Oncotarget. 2017; 8: 62681-62692
        • Vartolomei M.D.
        • Mathieu R.
        • Margulis V.
        • et al.
        Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.
        World J Urol. 2017; 35: 121-130
        • Vartolomei M.D.
        • Kimura S.
        • Ferro M.
        • et al.
        Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.
        World J Urol. 2018; 36: 1019-1029
        • Tang X.
        • Du P.
        • Yang Y.
        The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis.
        Int J Clin Oncol. 2017; 22: 817-825
        • Martha O.
        • Porav-Hodade D.
        • Bălan D.
        • et al.
        Easily available blood test neutrophil-to-lymphocyte ratio predicts progression in high-risk non-muscle invasive bladder cancer.
        Rev Romana Med Lab. 2017; 25: 181-189
        • Ozyalvacli M.E.
        • Ozyalvacli G.
        • Kocaaslan R.
        • et al.
        Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer.
        Can Urol Assoc J. 2015; 9: E126-E131
        • Grover S.
        • Srivastava A.
        • Lee R.
        • Tewari A.K.
        • Te A.E.
        Role of inflammation in bladder function and interstitial cystitis.
        Ther Adv Urol. 2011; 3: 19-33
        • Babjuk M.
        • Oosterlinck W.
        • Sylvester R.
        • et al.
        EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
        Eur Urol. 2008; 54: 303-314
        • Lamm D.L.
        Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
        Clin Infect Dis. 2000; 31: S86-S90
        • Rink M.
        • Fajkovic H.
        • Cha E.K.
        • et al.
        Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma.
        Eur Urol. 2012; 61: 854-855
        • Favilla V.
        • Castelli T.
        • Urzì D.
        • et al.
        Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study.
        Int Braz J Urol. 2016; 42: 685-693
        • D’Andrea D.
        • Moschini M.
        • Gust K.
        • et al.
        Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer.
        Clin Genitourin Cancer. 2017; 15: e755-e764
        • Breau R.H.
        • Karnes R.J.
        • Farmer S.A.
        • et al.
        Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.
        BJU Int. 2014; 113: 900-906
        • Mbeutcha A.
        • Shariat S.F.
        • Rieken M.
        • et al.
        Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
        Urol Oncol. 2016; 34: 483.e17-483.e24
        • Ogihara K.
        • Kikuchi E.
        • Yuge K.
        • et al.
        The preoperative neutrophil-to-lymphocyte ratio is a novel biomarker for predicting worse clinical outcomes in non-muscle invasive bladder cancer patients with a previous history of smoking.
        Ann Surg Oncol. 2016; 23: 1039-1047
        • Mano R.
        • Baniel J.
        • Shoshany O.
        • et al.
        Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
        Urol Oncol. 2015; 33 (e1-e7): 67
        • Ojerholm E.
        • Smith A.
        • Hwang W.-T.
        • et al.
        Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 87 10.
        Cancer. 2017; 123: 794-801
        • Kang M.
        • Jeong C.W.
        • Kwak C.
        • Kim H.H.
        • Ku J.H.
        Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
        Oncotarget. 2017; 8: 12891-12901
        • Vartolomei M.D.
        • Porav-Hodade D.
        • Ferro M.
        • et al.
        Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis.
        Urol Oncol. 2018; https://doi.org/10.1016/j.urolonc.2018.05.014
        • Moschetta M.
        • Uccello M.
        • Kasenda B.
        • et al.
        Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1/PD-L1 blockade.
        BioMed Res Int. 2017; 2017: 1506824
        • Sacdalan D.B.
        • Lucero J.A.
        • Sacdalan D.L.
        Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
        Onco Targets Ther. 2018; 11: 955-965
        • Lalani A.-K.A.
        • Xie W.
        • Martini D.J.
        • et al.
        Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
        J Immunother Cancer. 2018; 6: 5
        • Bilen M.A.
        • Dutcher G.M.A.
        • Liu Y.
        • et al.
        Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab.
        Clin Genitourin Cancer. 2018; 16: e563-e575
        • Diem S.
        • Schmid S.
        • Krapf M.
        • et al.
        Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
        Lung Cancer. 2017; 111: 176-181
        • Cassidy M.R.
        • Wolchok R.E.
        • Zheng J.
        • et al.
        Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment.
        EBioMedicine. 2017; 18: 56-61
        • Mukherjee N.
        • Svatek R.S.
        • Mansour A.M.
        Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
        Urol Oncol. 2018; 36: 103-108
        • Resch I.
        • Shariat S.F.
        • Gust K.M.
        PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.
        Memo. 2018; 11: 43-46
        • Shariat S.F.
        • Svatek R.S.
        • Tilki D.
        • et al.
        International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
        BJU Int. 2010; 105: 1402-1412
        • Mathieu R.
        • Lucca I.
        • Rouprêt M.
        • Briganti A.
        • Shariat S.F.
        The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.
        Nat Rev Urol. 2016; 13: 471-479
        • Moschini M.
        • D’Andrea D.
        • Korn S.
        • et al.
        Characteristics and clinical significance of histological variants of bladder cancer.
        Nat Rev Urol. 2017; 14: 651-668
        • Rogers C.G.
        • Palapattu G.S.
        • Shariat S.F.
        • et al.
        Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
        J Urol. 2006; 175 ([discussion: 2053]): 2048-2053